Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome

Curr Opin Neurobiol. 2012 Oct;22(5):880-6. doi: 10.1016/j.conb.2012.05.002. Epub 2012 May 30.

Abstract

Down syndrome (DS) is a multi-faceted condition resulting in the most common genetic form of intellectual disability. Mouse models of DS, especially the Ts65Dn model, have been pivotal in furthering our understanding of the genetic, molecular and neurobiological mechanisms that underlie learning and memory impairments in DS. Cognitive and pharmacological insights from the Ts65Dn mouse model have led to remarkable translational progress in the development of therapeutic targets and in the emergence of DS clinical trials. Unravelling the pathogenic role of trisomic genes on human chromosome 21 and the genotype-phenotype relationship still remains a pertinent goal for tackling cognitive deficits in DS.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chromosomes, Human, Pair 21 / genetics
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / etiology*
  • Disease Models, Animal
  • Down Syndrome / complications*
  • Down Syndrome / genetics
  • Humans
  • Mice
  • Mice, Transgenic
  • Neuroprotective Agents / therapeutic use*

Substances

  • Neuroprotective Agents